Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease
Sponsor: Mayo Clinic
Suspended
Due to lack of funding
Listed as NCT03325322, this PHASE2 trial focuses on Chronic Kidney Diseases and Diabetes Mellitus and remains suspended. Sponsored by Mayo Clinic, it has been updated 16 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Suspended PHASE2
-
Jul 2025 — Feb 2026 [monthly]
Suspended PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
May 2024 — Jul 2024 [monthly]
Suspended PHASE2
▶ Show 11 earlier versions
-
May 2023 — May 2024 [monthly]
Suspended PHASE2
Status: Enrolling By Invitation → Suspended
-
Dec 2022 — May 2023 [monthly]
Enrolling By Invitation PHASE2
Status: Recruiting → Enrolling By Invitation
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2020 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jan 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .